The first and only anti-VEGF proven effective and safe for diabetic retinopathy (DR) with and without DME 1,13

LUCENTIS® (ranibizumab injection) is indicated for the treatment of patients with diabetic retinopathy, and for treatment of patients with diabetic macular edema (DME).

DR progresses in steps and may result in vision loss 12

DR severity is defined by imaging such as fundus photography or ultra-widefield fluorescein angiography and by disease features.

ETDRS, Early Treatment Diabetic Retinopathy Scale; VEGF, vascular endothelial growth factor.

Resources for your patients.
Simple, personalized ordering.
LUCENTIS Co-pay Card Program
Support for your patients with commercial insurance.
LUCENTIS Access Solutions
Genentech Access Solutions is your resource for access and reimbursement support services.